Supporting Information for

Pd-Catalyzed Multicomponent Reaction of Sulfonyl azide, Primary amines and Methyl α-lsocyanoacetates: Highly Efficient Synthesis of Tetrasubstituted Imidazolone Derivatives

Fei Wang, Pei Xu, Bei-Bei Liu, Shun-Yi Wang* and Shun-Jun Ji*

Key Laboratory of Organic Synthesis of Jiangsu Province, College of Chemistry, Chemical Engineering and Materials Science & Collaborative Innovation Center of Suzhou Nano Science and Technology, Soochow University, Suzhou, 215123, P. R. China E-mail: shunyi@suda.edu.cn; shunjun@suda.edu.cn

Contents

I. General Information	S2
II. Synthesis of Substrates	S2
III. General Procedure and Product Characterization	S4
1. General Procedure	S4
2. Product Characterization	S5
IV. References	S14
V. Copies of ¹ H NMR and ¹³ C NMR Spectra	S15

I. General Information

Unless otherwise noted, all commercially available compounds were used as provided without further purification. Solvents for chromatography were analytical grade and used without further purification. Anhydrous DMF, was purchased from Beijing InnoChem Science & Technology Co., Ltd. Analytical thin-layer chromatography (TLC) was performed on silica gel, visualized by irradiation with UV light. For column chromatography, 300-400 mesh silica gel was used. ¹H-NMR and ¹³C-NMR were recorded on a BRUKER 400 MHz spectrometer in CDCl₃. Chemical shifts (δ) were reported referenced to an internal tetramethylsilane standard or the CDCl₃ residual peak (δ 7.26) for ¹H NMR. Chemical shifts of ¹³C NMR are reported relative to CDCl₃ (δ 77.16). Data are reported in the following order: chemical shift (δ) in ppm; multiplicities are indicated s (singlet), bs (broad singlet), d (doublet), t (triplet), m (multiplet); coupling constants (J) are in Hertz (Hz). IR spectra were recorded on a BRUKER VERTEX 70 spectrophotometer and are reported in terms of frequency of absorption (cm⁻¹). HRMS spectra were obtained by using BRUKER micrOTOF-Q III instrument with ESI source. The starting materials were isolated by SepaBean machine Flash Chromatography, which purchased from Santai Technologies Inc.

II. Synthesis of Substrates

General procedure for the synthesis of Substrate 1.¹

General procedure A:

$$MeO_2C \frown NC \xrightarrow{2 \text{ R-X, } K_2CO_3}{MeCN, 70^{\circ}C} \xrightarrow{R} MeO_2C \overleftarrow{NC}$$

To a solution of methyl α -isocyanoacetate (1 equiv) in MeCN (0.1 M) were added K₂CO₃ (4.4 equiv), TBAHS (0.1 equiv) and the corresponding alkyl halide (2 equiv). The reaction mixture was stirred at 70 °C for 12 hours. The reaction mixture was cooled to room temperature, quenched with a saturated aqueous solution of NaHCO₃ and extracted with DCM (3 times). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel to afford the pure product.

General procedure B:

$$\begin{array}{c} R \\ HO_2C \\ \hline NH_2 \\ \hline MeOH \\ \hline MeO_2C \\ \hline NH_2 \\ \hline MeO_2C \\ \hline NH_2 \\ \hline HCO_2H \\ \hline HCO_2H \\ \hline MeO_2C \\ \hline NHCHO \\ \hline MeO_2C \\ \hline NHCHO \\ \hline DCM, -30^{\circ}C \\ \hline NHCO_2C \\ \hline NHCHO \\ \hline NH$$

To a solution of Phenylalanine in methanol was added SOCl₂. The reaction mixture was stirred at RT for 2 hours and evaporated to dryness to give the corresponding methyl ester hydrochloride which was dissolved in NaOH (3M) and extraceted with DCM (3 times). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure.

The resulting amine was directly used without further purification.

A solution of formic acid (100 equiv) and Ac_2O (10 equiv) was stirred at 60 °C for 1 hour. After cooling down the reaction mixture to room temperature the amine was added. The reaction mixture was stirred at RT for 2 hours and evaporated to dryness to give the corresponding formamide which was directly used without further purification.

To a solution of the formamide in DCM (0.3 M) was added triethylamine (2.7 equiv). The reaction mixture was cooled to -30 $^{\circ}$ C. POCl₃ (1.2 equiv) was added and the solution was stirred at -30 $^{\circ}$ C with TLC monitoring (around 3h). The reaction mixture was cooled to room temperature, quenched with a saturated aqueous solution of NaHCO₃ and extracted with DCM (3 times). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel (Eluent: PE/AcOEt: 9/1 to 7/3) to afford the desired isocyanoacetate.

General procedure C:

Bn R-X, NaH Bn R-X, NaH MeO₂C NC DMF, RT to 50°C MeO₂C NC

To a solution of methyl 2-isocyano-3-phenylpropanoate (1 equiv) in DMF (0.1 M) was added portionwise NaH (1.5 equiv). After 30 minutes, the corresponding alkyl halide (1.5 equiv) was added dropwise. The reaction mixture was stirred at 50 °C for 12 hours. The reaction mixture was cooled to room temperature, quenched with a saturated aqueous solution of NaHCO₃ and extracted with DCM (3 times). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel to afford the pure product.

General procedure D:

$$\begin{array}{ccc} & \text{Ph} & \xrightarrow{\text{R-X, DBU}} & \text{Ph} \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & \\ & & & & \\ & & & & \\ & & & & \\ & & & & \\ & &$$

To a solution of methyl 2-isocyano-2-phenylacetate (1 equiv) in DCE (0.1 M) were added DBU (1.1 equiv) and the corresponding alkyl halide (1.5 equiv). The reaction mixture was stirred at 80 °C for 12 hours. The reaction mixture was cooled to room temperature, quenched with a saturated aqueous solution of NaHCO₃ and extracted with DCM (3 times). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The crude product was purified by flash chromatography on silica gel to afford the pure product.

General procedure for the synthesis of sulfonyl azides.²

$$\begin{array}{c} O \\ R \\ \hline CI \end{array} + NaN_3 \xrightarrow{\text{Acetone / } H_2O} & O \\ \hline rt, overnight \end{array} \xrightarrow{O} R \\ \hline S \\ \hline N_3 \end{array}$$

To a solution of sodium azide (2.0 g, 30 mmol) in water (10 mL) was added dropwise over 1h a solution of sulfonyl chloride (20 mmol) in acetone (20 mL) at 0 °C. The reaction mixture was warmed up to room temperature and stirred for 11 h. Acetone was removed under reduced pressure

and the reaction mixture was extracted with EtOAc (30 mL x 3). The combined organic layers were dried over MgSO₄ and solvent was removed under reduced pressure. Crude product was used without further purification.

III .General Procedure and Product Characterization

1. General Procedure for the Formation of 5a

A representative procedure synthesis of N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonamide (5a) is shown below.

In a 25 mL Schlenk tube, to a mixture of methyl 2-benzyl-2-isocyano-3-phenylpropanoate **1a** (0.3 mmol, 1.5 equiv), *p*-toluidine **2a** (0.2 mmol, 1.0 equiv), 4-methylbenzenesulfonyl azide **3a** (0.3 mmol, 1.5 equiv), Pd(PPh₃)₄ (5 mol %), PPh₃ (10 mol %) were added in 2 mL anhydrous DMF. The system was under the Ar at 90 °C (checked by TLC). After 12h, cooled to rt. The system was extracted with DCM (3 times). The combined organic layers were dried over Na₂SO₄ and solvent was removed under reduced pressure. The residue was purified by flash column chromatography with ethyl acetate and petroleum ether (EA : PE = 1 : 5) as eluents to afford pure product **5a**.



Figure1. Crystal structure of 5a (CCDC 1904592).

The procedure scale-up synthesis of N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonamide (5a) is shown below.

In a 25 mL Schlenk tube, to a mixture of methyl 2-benzyl-2-isocyano-3-phenylpropanoate **1a** (1.5 mmol, 1.5 equiv), *p*-toluidine **2a** (1 mmol, 1.0 equiv), 4-methylbenzenesulfonyl azide **3a** (1.5 mmol, 1.5 equiv), Pd(PPh₃)₄ (5 mol %), PPh₃ (10 mol %) were added in 5 mL anhydrous DMF. The system was under the Ar at 90 °C (checked by TLC). After 16h, cooled to rt. The system was

extracted with DCM (3 times). The combined organic layers were dried over Na_2SO_4 and solvent was removed under reduced pressure. The residue was purified by flash column chromatography with ethyl acetate and petroleum ether (EA : PE = 1 : 5) as eluents to afford pure product **5a**.



2. Product Characterization



N-(4,4-dibenzyl-5-oxo-1-phenyl-4,5-dihydro-1H-imidazol-2-yl)-4methylbenzenesulfonamide (4a)

Yield: 85% (86.6 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3297, 2988, 2973, 2361, 2340, 1760, 1623, 1394, 1268, 1078, 1052, 894, 685, 668, 604. ¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 7.55 (d, *J* = 7.8 Hz, 2H), 7.26 (s, 10H), 7.20 (s, 5H), 6.32 (d, *J* = 7.3 Hz, 2H), 3.33 (d, *J* = 13.6 Hz, 2H), 3.13 (d, *J* = 13.7 Hz, 2H), 2.40 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.3, 155.3, 144.0, 139.5, 133.9, 133.8, 130.4, 130.3, 129.4, 129.0, 128.7, 127.7, 127.2, 126.2, 69.3, 42.8, 21.6. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₀H₂₈N₃O₃S(M+H)⁺: 510.1851, found 510.1844.



N-(4,4-dibenzyl-1-(4-methoxyphenyl)-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonamide (4b)

Yield: 94% (101.9 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹):3320, 1763, 1618, 1514, 1451, 1255, 1154, 1119, 1076, 1025, 900, 847, 750, 675. ¹H NMR (400 MHz, CDCl₃) δ 8.49 (s, 1H), 7.56 (d, *J* = 7.8 Hz, 2H), 7.26 (s, 10H), 7.19 (d, *J* = 7.8 Hz, 2H), 6.67 (d, *J* = 8.4 Hz, 2H), 6.20 (d, *J* = 8.4 Hz, 2H), 3.68 (s, 3H), 3.30 (d, *J* = 13.5 Hz, 2H), 3.12 (d, *J* = 13.7 Hz, 2H), 2.39 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.6, 159.7, 155.5, 142.9, 139.5, 133.9, 130.3, 129.4, 128.6, 128.4, 127.7, 126.2, 123.0, 114.3, 69.3, 55.4, 42.7, 21.6. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₁H₂₉N₃O₄SNa(M+Na)⁺:562.1776, found 562.1750.



N-(4,4-dibenzyl-1-(4-(tert-butyl)phenyl)-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonamide (4c)

Yield: 74% (83.5 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3350, 2967, 2360, 2341, 1769, 1623, 1264, 1117, 1071, 900, 852, 753, 662, 602. ¹H NMR (400 MHz, CDCl₃) δ 8.41 (s, 1H), 7.56 (s, 2H), 7.23 (d, *J* = 21.2 Hz, 14H), 6.40–6.17 (m, 2H), 3.33 (d, *J* = 13.7 Hz, 2H), 3.11 (d, *J* = 13.6 Hz, 2H), 2.41 (s, 3H), 1.22 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 155.6, 151.8, 142.9, 139.6, 133.8, 130.3, 129.4, 128.7, 127.7, 126.5, 126.2, 126.0, 100.1, 69.2, 42.8, 34.7, 31.3, 21.7. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₄H₃₆N₃O₃S (M+H)⁺ :566.2477, found 566.2453.



N-(4,4-dibenzyl-1-(3,5-dimethylphenyl)-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4methylbenzenesulfonamide (4d)

Yield: 57% (59.7 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3336, 2363, 1766, 1616, 1453, 1267,1074, 946, 859, 812, 753, 703, 687, 646, 603. ¹H NMR (400 MHz, CDCl₃) δ 8.35 (s, 1H), 7.56 (d, *J* = 7.9 Hz, 2H), 7.26 (d, *J* = 7.6 Hz, 10H), 7.20 (d, *J* = 7.9 Hz, 2H), 6.84 (s, 1H), 5.85 (s, 2H), 3.31 (d, *J* = 13.6 Hz, 2H), 3.11 (d, *J* = 13.7 Hz, 2H), 2.41 (s, 3H), 2.13 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 155.6, 142.9, 139.6, 138.6, 133.8, 130.9, 130.4, 130.2, 129.3, 128.7, 127.7, 126.2, 124.9, 69.2, 42.8, 21.6, 21.1. HRMS (ESI⁺, MeCN) m/z calcd for C₃₂H₃₂N₃O₃S (M+H)⁺ :538.2164, found 538.2155.



N-(4,4-dibenzyl-1-(4-fluorophenyl)-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4methylbenzenesulfonamide (4e)

Yield: 79% (83.1 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3314, 2360, 2341, 1759, 1627, 1508, 1392, 1152, 1075, 898, 850, 811, 703, 673. ¹**H NMR** (400 MHz, CDCl₃) δ 8.46 (s, 1H), 7.56 (d, *J* = 7.9 Hz, 2H), 7.27 (s, 12H), 6.86 (t, *J* = 8.5 Hz, 2H), 6.35–6.20 (m, 2H), 3.33 (d, *J* = 13.6 Hz, 2H), 3.13 (d, *J* = 13.7 Hz, 2H), 2.40 (s,

3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.2, 162.5(*J*=248.2), 155.1, 143.1, 139.4, 133.8, 129.5(0)(*J*=164.8), 129.4(5), 129.1(*J*=8.8), 128.6, 127.8, 126.2, 116.1(*J*=23.0), 69.5, 42.8, 21.7. HRMS (ESI⁺, MeCN) m/z calcd for C₃₀H₂₇FN₃O₃S (M+H)⁺:528.1757, found 528.1748.



N-(4,4-dibenzyl-1-(4-chlorophenyl)-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonamide (4f)

Yield: 83% (89.6 mg isolated). White solid. Mp: 207.2 °C -208.1 °C. **IR** (neat, v, cm⁻¹): 3299, 2362, 2341, 1759, 1270, 1119, 1074, 895, 846, 812, 700, 667. ¹H NMR (400 MHz, CDCl₃) δ 8.55 (s, 1H), 7.65 – 7.51 (m, 2H), 7.26 (s, 10H), 7.17 – 7.10 (m, 2H), 6.34 – 6.12 (m, 2H), 3.31 (d, *J* = 13.3 Hz, 2H), 3.13 (d, *J* = 13.8 Hz, 2H), 2.39 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.1, 154.8, 143.2, 139.3, 134.9, 133.8, 130.3, 129.5, 129.2, 128.9, 128.7, 128.5, 127.8, 126.2, 69.6, 42.7, 21.7. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₀H₂₇ClN₃O₃S (M+H)⁺:544.1462, found 544.1277.



N-(4,4-dibenzyl-1-(4-bromophenyl)-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4methylbenzenesulfonamide (4g)

Yield: 67% (78.7 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3295, 2361, 1760, 1625, 1559, 1444, 1386, 1270, 1154, 1116, 1076, 897, 845, 747, 697. ¹H **NMR** (400 MHz, CDCl₃) δ 8.55 (s, 1H), 7.56 (d, *J* = 8.0 Hz, 2H), 7.25 (s, 14H), 6.17 (d, *J* = 8.4 Hz, 2H), 3.29 (d, *J* = 13.5 Hz, 2H), 3.12 (d, *J* = 13.9 Hz, 2H), 2.38 (s, 3H). ¹³C **NMR** (100 MHz, CDCl₃) δ 173.0, 154.7, 143.2, 139.3, 133.8, 132.2, 130.3, 129.5, 129.4, 128.7, 128.6, 127.8, 126.2, 123.0, 69.6, 42.7, 21.7. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₀H₂₇BrN₃O₃S (M+H)⁺:588.0957, found 588.0952.



N-(4,4-dibenzyl-5-oxo-1-propyl-4,5-dihydro-1H-imidazol-2-yl)-4methylbenzenesulfonamide (4j) Yield: 48% (62.6 mg isolated). Yellow solid. Mp: 139.6 °C -140.2 °C. IR (neat, v, cm⁻¹):

3313, 2961, 2920, 2359, 1753, 1646, 1593, 1471, 1263, 1145, 1073, 972, 817, 751, 677. ¹**H NMR** (400 MHz, CDCl₃) δ 7.92 (s, 1H), 7.61 (d, *J* = 7.7 Hz, 2H), 7.23 (d, *J* = 16.5 Hz, 8H), 7.14 (s, 4H), 3.22 (d, *J* = 13.7 Hz, 2H), 3.00 (d, *J* = 12.4 Hz, 4H), 2.43 (s, 3H), 1.60 (s, 2H), 0.35 (s, 3H).
¹³**C NMR** (100 MHz, CDCl₃) δ 174.0, 155.9, 143.0, 139.5, 133.5, 130.2, 129.4, 128.7, 127.7, 126.3, 68.5, 42.8, 40.8, 21.7, 20.4, 10.8. **HRMS** (ESI⁺, MeCN) m/z calcd for C₂₇H₂₉N₃O₃SNa (M+Na)⁺: 498.1827, found 498.1829.



N-(4,4-dibenzyl-1-isopropyl-5-oxo-4,5-dihydro-1H-imidazol-2-yl)-4methylbenzenesulfonamide (4k)

Yield: 95% (90.3 mg isolated). White solid. Mp: 164.5 °C -165.5 °C. **IR** (neat, v, cm⁻¹): 3334, 1748, 1614, 1495, 1387, 1267, 1066, 944, 869, 750, 702, 676. ¹H NMR (300 MHz, CDCl₃) δ 8.22 (s, 1H), 7.61 (d, *J* = 7.9 Hz, 2H), 7.22 (d, *J* = 14.0 Hz, 12H), 3.96 – 3.73 (m, 1H), 3.22 (d, *J* = 13.6 Hz, 2H), 3.02 (d, *J* = 13.7 Hz, 2H), 2.42 (s, 3H), 0.78 (d, *J* = 6.9 Hz, 6H). ¹³C NMR (75 MHz, CDCl₃) δ 174.1, 155.5, 142.9, 139.8, 133.8, 130.3, 129.4, 128.5, 127.5, 126.2, 68.2, 44.6, 42.7, 21.6, 18.6. **HRMS** (ESI⁺, MeCN) m/z calcd for C₂₇H₂₉N₃O₃SNa (M+Na)⁺:498.1827, found 498.1817.



methyl 2-(4,4-dibenzyl-2-((4-methylphenyl)sulfonamido)-5-oxo-4,5-dihydro-1Himidazol-1-yl)acetate (4l)

Yield: 66% (100.5 mg isolated). White solid. Mp: 176.1 °C-176.5 °C. **IR** (neat, v, cm⁻¹): 3321, 2361, 1760, 1622, 1390, 1270, 1205, 1151, 1119, 1079, 975, 831, 810, 744, 684. ¹**H NMR** (400 MHz, CDCl₃) δ 8.16 (s, 1H), 7.56 (d, *J* = 7.9 Hz, 2H), 7.29 – 7.12 (m, 12H), 3.79 (s, 2H), 3.32 (s, 3H), 3.24 (d, *J* = 13.7 Hz, 2H), 3.06 (d, *J* = 13.8 Hz, 2H), 2.42 (d, *J* = 13.7 Hz, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 173.5, 166.3, 154.7, 139.2, 133.5, 130.3, 129.4, 128.7, 127.7, 126.2, 69.1, 52.4, 42.6, 39.8, 21.6. **HRMS** (ESI⁺, MeCN) m/z calcd for C₂₇H₂₇N₃O₅SNa (M+Na)⁺:528.1569, found 528.1562.



methyl 2-(4,4-dibenzyl-2-((4-methylphenyl)sulfonamido)-5-oxo-4,5-dihydro-1Himidazol-1-yl)-3-phenylpropanoate (4m)

Yield: 88% (157.0 mg isolated). White solid. Mp: 154.3 °C -155.2 °C. **IR** (neat, v, cm⁻¹): 3303, 2360, 1760, 1748, 1633, 1494, 1399, 1275, 1228, 1078, 867, 817, 748, 699. ¹**H NMR** (400 MHz, CDCl₃) δ 7.75 (s, 1H), 7.61 (d, *J* = 7.9 Hz, 2H), 7.37 – 7.29 (m, 3H), 7.26 (d, *J* = 7.3 Hz, 2H), 7.15 (dt, *J* = 18.5, 7.7 Hz, 8H), 7.01 (d, *J* = 7.1 Hz, 4H), 4.75 (t, *J* = 7.8 Hz, 1H), 3.27 (dd, *J* = 14.3, 6.7 Hz, 1H), 3.14 (s, 3H), 3.01 (d, *J* = 13.8 Hz, 1H), 2.82 (dd, *J* = 13.2, 5.1 Hz, 3H), 2.43 (s, 3H), 1.65 (s, 1H). ¹³**C NMR** (100 MHz, CDCl₃) δ 173.3, 168.2, 153.9, 143.2, 139.3, 136.7, 133.5, 133.4, 130.5, 129.4, 129.4, 128.9, 128.6, 128.5, 127.9, 127.4, 127.0, 126.4, 67.7, 53.1, 52.4, 42.9, 41.1, 34.5, 21.7. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₄H₃₃N₃O₅SNa (M+Na)⁺:618.2039, found 618.2052.



methyl (E)-2-benzyl-2-((5-methyl-1,1-dioxido-1-(p-tolyl)-1,4-dihydro-113benzo[e][1,2,4]thiadiazin-3(2H)-ylidene)amino)-3-phenylpropanoate (4n') Yield: 90% (103.5 mg isolated). White solid. Mp: 148.7 °C -149.6 °C. IR (neat, v, cm⁻¹): 3326, 2362, 1731, 1547, 1375, 1270, 1217, 1139, 1083, 942, 777, 746, 662. ¹H NMR (400 MHz, CDCl₃) δ 8.76 (s, 1H), 8.00 (d, J = 7.9 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.08 (tt, J = 26.9, 7.3 Hz, 7H), 6.89 (d, J = 7.6 Hz, 2H), 6.78 (d, J = 7.5 Hz, 4H), 5.05 (s, 1H), 3.79 (d, J = 13.8 Hz, 2H), 3.66 (s, 3H), 3.28 (d, J = 13.8 Hz, 2H), 2.43 (s, 3H), 1.71 (s, 6H). ¹³C NMR (100 MHz, CDCl₃) δ 173.3, 152.5, 142.4, 141.2, 136.8, 135.6, 131.6, 129.9, 129.5, 128.9, 128.6, 128.5, 127.1, 126.4, 66.9, 52.7, 41.7, 21.6, 17.6. HRMS (ESI⁺, MeCN) m/z calcd for C₃₃H₃₆N₃O₄S (M+H)⁺: 570.2427, found 570.2409.



methyl (E)-2-benzyl-2-(((tert-butylamino)((4-

methylphenyl)sulfonamido)methylene)amino)-3-phenylpropanoate (4o')

Yield: 95% (99.0 mg isolated). White solid. Mp: 179.0 °C -180.2 °C. **IR** (neat, v, cm⁻¹): 3419, 3335, 2361, 1734, 1557, 1405, 1140, 1086, 1033, 943, 771, 705, 658. ¹H NMR (400 MHz, CDCl₃) δ 7.92 (d, *J* = 7.9 Hz, 2H), 7.56 (s, 1H), 7.28 (d, *J* = 8.0 Hz, 2H), 7.10 (d, *J* = 6.9 Hz, 6H), 6.80 (d, *J* = 6.9 Hz, 4H), 5.46 (s, 1H), 4.14 (d, *J* = 13.5 Hz, 2H), 3.82 (s, 3H), 3.11 (d, *J* = 13.4 Hz, 2H), 2.38 (s, 3H), 1.01 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 173.8, 152.3, 142.2, 141.3, 136.0, 129.6, 129.4, 128.2, 127.0, 126.2, 69.0, 52.9, 51.0, 40.9, 29.3, 21.5. **HRMS** (ESI⁺, MeCN) m/z calcd for C₂₉H₃₆N₃O₄S (M+H)⁺:522.2427, found 522.2442.



N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonamide (5a)

Yield: 99% (108.2 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3303, 2363, 1760, 1621, 1516, 1436, 1388, 1270, 1154, 1117, 1077, 899, 747, 675. ¹H NMR (400 MHz, CDCl₃) δ 8.40 (s, 1H), 7.55 (d, *J* = 7.7 Hz, 2H), 7.25 (s, 10H), 7.20 (d, *J* = 7.8 Hz, 2H), 6.98 (d, *J* = 7.6 Hz, 2H), 6.20 (d, *J* = 7.7 Hz, 2H), 3.32 (d, *J* = 13.6 Hz, 2H), 3.11 (d, *J* = 13.6 Hz, 2H), 2.40 (s, 3H), 2.23 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.4, 155.5, 142.9, 139.5, 139.0, 133.8, 130.3, 129.7, 129.4, 128.7, 127.8, 127.7, 126.9, 126.2, 69.2, 42.8, 21.6, 21.2. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₁H₄₀N₃O₃S (M+H)⁺: 524.2008, found 524.2011.



N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4methoxybenzenesulfonamide (5b)

Yield:94% (101.2 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3292, 2987, 2360, 1759, 1634, 1437, 1258, 1120, 1078, 897, 831, 755, 730, 675. ¹H NMR (400 MHz, CDCl₃) δ 8.43 (s, 1H), 7.60 (d, *J* = 8.4 Hz, 2H), 7.26 (s, 10H), 6.97 (d, *J* = 7.8 Hz, 2H), 6.86 (d, *J* = 8.4 Hz, 2H), 6.20 (d, *J* = 7.9 Hz, 2H), 3.82 (s, 3H), 3.31 (d, *J* = 13.6 Hz, 2H), 3.12 (d, *J* = 13.6 Hz, 2H), 2.23 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.5, 162.6, 155.3, 139.0, 134.4, 133.9, 130.3, 129.7, 128.6, 128.3, 127.8, 127.7, 126.9, 113.9, 69.2, 55.7, 42.8, 21.2. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₁H₃₀N₃O₄S(M+H)⁺:540.1957, found 540.1902.



N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)benzenesulfonamide (5c)

Yield: 60% (61.3 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3312, 2362, 2332, 1761, 1625, 1515, 1390, 1272, 1120, 1076, 898, 846, 717, 652. ¹H NMR (400 MHz, CDCl₃) δ 8.41 (s, 1H), 7.72 (d, *J* = 7.7 Hz, 2H), 7.57 (d, *J* = 8.1 Hz, 1H), 7.47 (t, *J* = 7.9 Hz, 2H), 7.31 (s, 10H), 7.05 (d, *J* = 7.8 Hz, 2H), 6.27 (d, *J* = 8.0 Hz, 2H), 3.40 (d, *J* = 13.5 Hz, 2H), 3.17 (d, *J* = 13.7 Hz, 2H), 2.30 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.4, 155.6, 142.4, 139.1, 133.7, 132.3, 130.3, 129.7, 128.8, 128.7, 127.8,

127.7, 126.9, 126.2, 69.2, 42.8, 21.3. **HRMS** (ESI⁺, MeCN) m/z calcd for $C_{30}H_{28}N_3O_3S$ (M+H)⁺:510.1851, found 510.1835.



N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4-fluorobenzenesulfonamide (5d)

Yield:90% (96.4 mg isolated). White solid. Mp: 196.2°C-197.3°C. **IR** (neat, v, cm⁻¹): 3322, 2361, 1765, 1625, 1494, 1394, 1239, 1122, 1076, 897, 749, 672. ¹**H** NMR (400 MHz, CDCl₃) δ 8.36 (s, 1H), 7.64 (dd, *J* = 8.6, 5.0 Hz, 2H), 7.33 – 7.19 (m, 10H), 7.06 (t, *J* = 8.3 Hz, 2H), 6.99 (d, *J* = 7.9 Hz, 2H), 6.20 (d, *J* = 7.9 Hz, 2H), 3.34 (d, *J* = 13.3 Hz, 2H), 3.11 (d, *J* = 13.6 Hz, 2H), 2.24 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.4, 164.8(*J*=252.3), 155.6, 139.2, 138.5(0), 138.4(7), 133.7, 129.7, 129.5(*J*=158.9), 128.8(*J*=9.2), 127.8, 127.6, 126.9, 115.9 (*J*=23.0), 69.3, 42.8, 21.3. HRMS (ESI⁺, MeCN) m/z calcd for C₃₀H₂₇FN₃O₃S (M+H)⁺:528.1757, found 528.1751.



4-chloro-N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)benzenesulfonamide (5e)

Yield: 83% (90.7 mg isolated). White solid. Mp: 202.3°C-203.1°C. **IR** (neat, v, cm⁻¹): 3307, 2973, 2362, 1766, 1617, 1515, 1436, 1388, 1269, 1155, 1077, 899, 829, 754, 660. ¹**H NMR** (400 MHz, CDCl₃) δ 8.34 (s, 1H), 7.56 (d, *J* = 8.1 Hz, 2H), 7.35 (d, *J* = 8.2 Hz, 2H), 7.25 (q, *J* = 7.5, 7.1 Hz, 10H), 6.99 (d, *J* = 7.9 Hz, 2H), 6.19 (d, *J* = 7.9 Hz, 2H), 3.34 (d, *J* = 13.7 Hz, 2H), 3.10 (d, *J* = 13.7 Hz, 2H), 2.24 (s, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 173.3, 155.7, 140.8, 139.2, 138.6, 133.7, 130.3, 129.8, 129.0, 128.7, 127.8, 127.7, 127.6, 126.9, 69.4, 42.8, 21.3. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₀H₂₆ClN₃O₃SNa (M+Na)⁺ :566.1281, found 566.1271.



N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4iodobenzenesulfonamide (5f)

Yield: 71% (89.9 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3350, 2987, 2361, 1760, 1619, 1438, 1386, 1263, 1073, 1007, 897, 725, 601. ¹H NMR (400 MHz,

CDCl₃) δ 8.25 (s, 1H), 7.78 – 7.71 (m, 2H), 7.36 – 7.32 (m, 2H), 7.30 – 7.27 (m, 3H), 7.25 – 7.24 (m, 1H), 7.22 (dd, *J* = 7.7, 1.9 Hz, 4H), 7.00 (d, *J* = 8.0 Hz, 2H), 6.22 – 6.17 (m, 2H), 3.35 (d, *J* = 13.7 Hz, 2H), 3.10 (d, *J* = 13.7 Hz, 2H), 2.25 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 173.3, 155.7, 142.0, 139.3, 138.0, 133.6, 130.3, 129.8, 128.7, 127.9, 127.7, 127.6, 126.9, 99.5, 69.3, 42.9, 21.3. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₀H₂₇IN₃O₃S (M+H)⁺:636.0818, found 636.0828.



4-cyano-N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)benzenesulfonamide (5g)

Yield: 71% (76.2 mg isolated). White solid. Mp: 205.6 °C -206.2 °C. **IR** (neat, v, cm⁻¹): 3340, 2362, 1760, 1626, 1515, 1451, 1388, 1278, 1152, 1076, 900, 848, 754, 646. ¹**H NMR** (400 MHz, CDCl₃) δ 8.26 (s, 1H), 7.68 (s, 4H), 7.27 (tt, *J* = 13.5, 7.0 Hz, 10H), 7.00 (d, *J* = 7.9 Hz, 2H), 6.19 (d, *J* = 7.9 Hz, 2H), 3.38 (d, *J* = 13.7 Hz, 2H), 3.11 (d, *J* = 13.7 Hz, 2H), 2.25 (s, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 219.2, 173.2, 156.0, 146.3, 139.4, 133.6, 132.6, 130.2, 129.8, 128.8, 127.9, 127.4, 126.8, 117.6, 115.9, 107.8, 69.4, 42.8, 21.3. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₁H₂₇N₄O₃S (M+H)⁺ :535.1804 found 535.1770.



4-methyl-N-(4-methyl-5-oxo-4-phenyl-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)benzenesulfonamide (6d)

Yield: 68% (59.2 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3313, 2360, 1760, 1628, 1515, 1440, 1379, 1264, 1125, 1076, 915, 879, 785, 740, 676. ¹**H NMR** (400 MHz, CDCl₃) δ 8.30 (s, 1H), 7.71 (d, *J* = 7.8 Hz, 2H), 7.42 (d, *J* = 7.1 Hz, 2H), 7.32 (d, *J* = 7.7 Hz, 3H), 7.20 (d, *J* = 8.4 Hz, 2H), 7.11 (d, *J* = 7.8 Hz, 2H), 7.01 (d, *J* = 8.1 Hz, 2H), 2.35 (s, 3H), 2.27 (s, 3H), 1.87 (s, 3H). ¹³**C NMR** (100 MHz, CDCl₃) δ 173.4, 155.3, 143.3, 139.2, 139.1, 137.7, 129.8, 129.6, 129.3, 129.0, 128.2, 127.0, 126.4, 125.2, 64.7, 25.6, 21.7, 21.3. **HRMS** (ESI⁺, MeCN) m/z calcd for C₂₄H₂₃N₃O₃SNa (M+Na)⁺:456.1358 found 456.1332.



N-(4-benzyl-5-oxo-4-phenyl-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonamide (6e)

Yield: 75% (76.8 mg isolated). White solid. Mp: 209.2 °C -209.8°C. **IR** (neat, v, cm⁻¹): 3303, 2362, 1758, 1635, 1433, 1264, 1138, 1112, 1077, 891, 692, 670, 644. ¹**H NMR** (400 MHz, CDCl₃) δ 8.57 (s, 1H), 7.65 (dd, *J* = 13.1, 7.6 Hz, 4H), 7.42 (q, *J* = 8.0, 7.6 Hz, 3H), 7.24 (h, *J* = 9.4, 7.8 Hz, 7H), 7.06 (d, *J* = 8.0 Hz, 2H), 6.56 (d, *J* = 7.9 Hz, 2H), 3.68 (d, *J* = 13.6 Hz, 1H), 3.30 (d, *J* = 13.6 Hz, 1H), 2.42 (s, 3H), 2.28 (s, 3H). ¹³C **NMR** (100 MHz, CDCl₃) δ 172.4, 155.4, 144.2, 143.1, 139.3, 139.1, 136.7, 133.4, 130.6, 129.7, 129.4, 129.2, 129.1, 128.7, 127.9, 127.1, 126.4, 125.7, 69.1, 45.4, 21.7, 21.3. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₀H₂₇N₃O₃SNa (M+Na)⁺:532.1671 found532.1676.



N-(4,4-diallyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4methylbenzenesulfonamide (6f)

Yield: 48% (40.5 mg isolated). White solid. Mp: 181.7 °C -182.6°C. **IR** (neat, v, cm⁻¹): 3291, 2982, 2360, 1763, 1608, 1380, 1279, 1122, 1079, 891, 844, 814, 731, 677. ¹**H NMR** (400 MHz, CDCl₃) δ 8.02 (s, 1H), 7.76 (d, *J* = 7.9 Hz, 2H), 7.29 – 7.23 (m, 2H), 7.18 (d, *J* = 7.9 Hz, 2H), 7.00 (d, *J* = 7.9 Hz, 2H), 5.67 (dd, *J* = 16.9, 9.0 Hz, 2H), 5.21 (t, *J* = 12.0 Hz, 4H), 2.58 (qd, *J* = 13.9, 7.4 Hz, 4H), 2.38 (d, *J* = 25.8 Hz, 6H). ¹³**C NMR** (100 MHz, CDCl₃) δ 173.7, 156.0, 143.2, 139.4, 139.2, 129.8, 129.6, 129.5, 128.2, 127.1, 126.4, 121.9, 66.5, 40.8, 21.7, 21.4. **HRMS** (ESI⁺, MeCN) m/z calcd for C₂₃H₂₅N₃O₃SNa (M+Na)⁺:446.1514 found 446.1531.



N-(4,4-bis(4-methylbenzyl)-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)-4-methylbenzenesulfonamide(6g)

Yield: 69% (113.7 mg isolated). White solid. Mp: >210°C. **IR** (neat, v, cm⁻¹): 3305, 1759, 1637, 1514, 1441, 1269, 1153, 1077, 899, 736, 672. ¹**H NMR** (400 MHz, CDCl₃) δ 8.17 (s, 1H), 7.56 (d, *J* = 7.9 Hz, 2H), 7.21 (d, *J* = 7.9 Hz, 2H), 7.12 – 6.96 (m, 10H), 6.27 (d, *J* = 7.8 Hz, 2H), 3.27 (d, *J* = 13.7 Hz, 2H), 3.03 (d, *J* = 13.7 Hz, 2H), 2.42 (s,

3H), 2.28 (d, J = 16.3 Hz, 9H). ¹³C NMR (100 MHz, CDCl₃) δ 173.6, 155.5, 142.8, 139.7, 139.0, 137.3, 130.6, 130.1, 129.6, 129.4, 129.3, 127.9, 127.0, 126.3, 69.1, 42.4, 21.7, 21.3, 21.2. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₃H₃₂N₃O₃SNa (M+Na)⁺:574.2140 found 574.2150.



N-(4,4-dibenzyl-5-oxo-1-(p-tolyl)-4,5-dihydro-1H-imidazol-2-yl)benzamide (7a) Yield: 59% (56.2 mg isolated). White solid. Mp: 138.6-139.2. **IR** (neat, v, cm⁻¹): 3291, 1743, 1631, 1584, 1513, 1443, 1323, 1260, 1168, 1098, 792, 700, 602. ¹H NMR (400 MHz, CDCl₃) δ 9.84 (s, 1H), 7.97 – 7.90 (m, 2H), 7.45 – 7.39 (m, 1H), 7.31 (d, *J* = 7.8 Hz, 2H), 7.28 (d, *J* = 1.9 Hz, 2H), 7.26 (d, *J* = 1.6 Hz, 6H), 7.25 (d, *J* = 2.2 Hz, 1H), 7.17 (tq, *J* = 4.1, 2.5, 1.9 Hz, 1H), 7.12 (d, *J* = 8.0 Hz, 2H), 6.54 – 6.48 (m, 2H), 3.40 (d, *J* = 13.6 Hz, 2H), 3.11 (d, *J* = 13.7 Hz, 2H), 2.34 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ 179.3, 174.1, 160.2, 138.6, 136.8, 133.8, 132.2, 130.3, 130.0, 129.7, 129.5, 128.7, 128.1, 127.8, 127.0, 68.8, 43.1, 21.4. **HRMS** (ESI⁺, MeCN) m/z calcd for C₃₁H₂₇N₃O₂Na (M+Na)⁺:496.2001 found 496.2018.

IV. References

- (1) (a) [1] A. Clemenceau, Q.Wang, J. Zhu, Org. Lett. 2017, 19, 4872 4875.
 (b) A. Clemenceau, Q. Wang, J. Zhu, Org. Lett. 2018, 20, 126–129
 (c) Ito, Y.; Higuchi, N.; Murakami, M. Tetrahedron Lett. 1988, 29, 5151.
 (d) N. Elders, R. F. Schmitz, F. J. J. de Kanter, E. Ruijter, M. B. Groen, R. V. A. Orru. J. Org. Chem. 2007, 72, 6135-6142.
- (2) (a) Z.-Y, Gu, Y. Liu, F. Wang, X.-G, Bao, S.-Y, Wang, S. -J Ji, ACS Catal. 2017, 7, 3893–3899
 (b) T. Jiang, Z. -Y, Gu, L. Yin, S. -Y, Wang, S. -J, Ji, J. Org. Chem. 2017, 82, 7913–7919.



S15



S16





210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)









S21



















S27









S29















S34



S35











210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)

¹H NMR Spectra of **7a**



210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 f1 (ppm)